Susan L. Greenspan

TL;DR: Changes in the volumetric density of trabecular bone, the cortical volume at the hip, and levels of markers of bone turnover suggest that the concurrent use of alendronate may reduce the anabolic effects of parathyroid hormone.

TL;DR: It is concluded that among elderly fallers--in most of whom hip BMD is already less than the fracture threshold--fall characteristics and body habitus are important risk factors for hip fracture and touch on a domain entirely missed by knowledge of BMD.

TL;DR: After one year of parathyroid hormone (1-84), densitometric gains appear to be maintained or increased with alendronate but lost if parathyro hormone is not followed by an antiresorptive agent, which has clinical implications for therapeutic choices after the discontinuation of par Kathyroid hormone.

TL;DR: The ASBMR Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered, and in women at high risk, older women, those with a low hip T-score or high fracture risk score, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be consideration.

TL;DR: A meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis demonstrated that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures.